In prostate cancer, it was identified that downregulation of DAB2IP expression promotes resistance to ionizing radiation [15], initiates epithelial-to-mesenchymal transition [11] and drives tumor growth and metastasis [16]. Here, DAB2IP is linked to prostate carcinoma.